Concerta 36 mg Extended-Release for a 14-Year-Old
Concerta 36 mg once daily in the morning is an appropriate and FDA-approved dose for a 14-year-old adolescent with ADHD, and should be swallowed whole with liquids, never chewed or crushed. 1
Dosing Guidelines for Adolescents
For adolescents (ages 13-17), the FDA-approved dosing parameters are:
- Starting dose (if new to methylphenidate): 18 mg once daily in the morning
- Dose titration: May increase by 18 mg/day at weekly intervals based on response
- Maximum dose for adolescents: 72 mg/day (higher than the 54 mg maximum for children 6-12 years) 1
The 36 mg dose represents a mid-range therapeutic dose that falls well within safe prescribing limits for this age group.
Administration Instructions
Critical administration details that directly impact efficacy 1:
- Take once daily in the morning
- Swallow tablet whole with liquids—never chew, divide, or crush
- May take with or without food
- The tablet shell may appear in stool (this is normal—the medication has already been absorbed)
The extended-release mechanism is designed to provide 12-hour symptom coverage, equivalent to three-times-daily immediate-release methylphenidate 2, 3.
Required Monitoring
Before starting and during treatment, monitor 4, 5, 1:
Cardiovascular:
- Blood pressure and heart rate at each visit
- Screen for personal or family history of structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or sudden cardiac death
- Consider ECG if cardiac risk factors present
Growth parameters:
- Height and weight at baseline and regularly during treatment
- Methylphenidate can cause growth suppression, though effects are typically modest 4, 6
Psychiatric:
- Screen for personal/family history of bipolar disorder, psychosis, or suicidal ideation before starting
- Monitor for new or worsening psychiatric symptoms (psychosis, mania, aggression, suicidal thoughts) 1
Other monitoring:
- Appetite and sleep quality
- Tics or Tourette's syndrome (assess family history; monitor for emergence/worsening)
- Periodic CBC, differential, and platelet counts during prolonged therapy 1
Expected Efficacy
Concerta demonstrates large effect sizes for reducing core ADHD symptoms (inattention, hyperactivity, impulsivity) with rapid onset of benefits 5, 2. Research shows:
- Symptom control lasting 12 hours post-dose 2
- Continued efficacy even after 2+ years of treatment 7
- Improvements in academic productivity, classroom behavior, and social functioning 2
Common Adverse Effects
Most frequent side effects to counsel patients about 5, 1:
- Decreased appetite (most common)
- Sleep disturbances/insomnia
- Headaches
- Increased blood pressure and heart rate
- Abdominal pain
- Irritability
These are generally dose-dependent and may improve with time or dose adjustment.
Critical Safety Warnings
Absolute contraindications 1:
- Known hypersensitivity to methylphenidate
- Current use or use within 14 days of MAO inhibitors
- Known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease
Black Box Warning: Concerta has high potential for abuse, misuse, and addiction. Assess abuse risk before prescribing, educate families about secure storage, and monitor for signs of misuse throughout treatment 1.
Clinical Context
Stimulants like methylphenidate are first-line pharmacotherapy for ADHD in adolescents, with stronger evidence than non-stimulants (atomoxetine, guanfacine, clonidine) 5. The 2019 AAP guidelines emphasize that medication should be part of a comprehensive treatment plan, though behavioral interventions alone are typically insufficient for moderate-to-severe ADHD in this age group 4.
Common pitfall: Families may discontinue medication during weekends or summers. However, ADHD impairment extends beyond school settings, and continuous treatment often provides better functional outcomes across all domains 4.
If inadequate response occurs after optimizing methylphenidate dosing (up to 72 mg/day), consider switching to lisdexamfetamine (another stimulant) before trying non-stimulants 5.